Correlation Between Karyopharm Therapeutics and Blueprint Medicines

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Blueprint Medicines Corp, you can compare the effects of market volatilities on Karyopharm Therapeutics and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Blueprint Medicines.

Diversification Opportunities for Karyopharm Therapeutics and Blueprint Medicines

-0.03

Correlation Coefficient

Karyopharm Therapeutics  Blueprint Medicines

Good diversification

The 3 months correlation between Karyopharm and Blueprint is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Blueprint Medicines go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Blueprint Medicines

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Blueprint Medicines. In addition to that, Karyopharm Therapeutics is 1.02 times more volatile than Blueprint Medicines Corp. It trades about -1.03 of its total potential returns per unit of risk. Blueprint Medicines Corp is currently generating about -0.12 per unit of volatility. If you would invest  9,463  in Blueprint Medicines Corp on September 27, 2024 and sell it today you would lose (417.00) from holding Blueprint Medicines Corp or give up 4.41% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Blueprint Medicines Corp

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Blueprint Medicines Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Blueprint Medicines Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, Blueprint Medicines is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders.

Pair Trading with Karyopharm Therapeutics and Blueprint Medicines

The main advantage of trading using opposite Karyopharm Therapeutics and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.

The idea behind Karyopharm Therapeutics and Blueprint Medicines Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.